Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1148-1155

  Niimi, K ^a   Maki, K ^b   Ikeda, F ^b   Holmes, A R ^a   Lamping, E ^a   Niimi, M ^c   Monk, B C ^a   Cannon, R D ^a,d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b ASTELLAS PHARMA INC   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AGAR; ANTIFUNGAL AGENT; CARRIER PROTEIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PROTEIN MFS; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ALLELE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL GENE; CANDIDA ALBICANS; CDR1 GENE; CDR2 GENE; CULTURE MEDIUM; DILUTION; DRUG POTENCY; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; GENE DELETION; GENE OVEREXPRESSION; LIQUID MICRODILUTION SUSCEPTIBILITY ASSAY; MDR1 GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE;

ANTIFUNGAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CANDIDA ALBICANS; DIFFUSION; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENES, MDR; LIPOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC;

EID: 33645785596     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1148-1155.2006     Document Type: Article

References (39)

1. Arikan, S., P. Yurdakul, and G. Hascelik. 2003. Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob. Agents Chemother. 47:2640-2643.
2. Arnaud, M. B., M. C. Costanzo, M. S. Skrzypek, G. Binkley, C. Lane, S. R. Miyasato, and G. Sherlock. 2005. The Candida Genome Database (CGD), a community resource for Candida albicans gene and protein information. Nucleic Acids Res. 33:D358-D363.
3. Bachmann, S. P., T. F. Patterson, and J. L. Lopez-Ribot. 2002. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J. Clin. Microbiol. 40:2228-2230.
4. Bartizal, C., and F. C. Odds. 2003. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:2100-2107.
5. Coste, A. T., M. Karababa, F. Ischer, J. Bille, and D. Sanglard. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3:1639-1652.
6. Denning, D. W. 2002. Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. 49:889-891.
7. Douglas, C. M., J. A. Marrinan, W. Li, and M. B. Kurtz. 1994. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-β-D-glucan synthase. J. Bacteriol. 176:5686-5696.
8. Ernst, E. J., E. E. Roling, C. R. Petzold, D. J. Keele, and M. E. Klepser. 2002. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. 46:3846-3853.
9. Hernandez, S., J. L. Lopez-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383.
10. Ikeda, F., K. Otomo, T. Nakai, Y. Morishita, K. Maki, S. Tawara, S. Mutoh, F. Matsumoto, and S. Kuwahara. 2002. In vitro activity of a new lipopeptide antifungal agent, micafungin, against a variety of clinically important fungi. Jpn. J. Chemother. 50:8-19.
11. Jones, T., N. A. Federspiel, H. Chibana, J. Dungan, S. Kalman, B. B. Magee, G. Newport, Y. R. Thorstenson, N. Agabian, P. T. Magee, R. W. Davis, and S. Scherer. 2004. The diploid genome sequence of Candida albicans. Proc. Natl. Acad. Sci. USA 101:7329-7334.
12. Kartsonis, N. A., J. Nielsen, and C. M. Douglas. 2003. Caspofungin: the first in a new class of antifungal agents. Drug Resist. Updat. 6:197-218.
13. Kurtz, M. B., G. Abruzzo, A. Flattery, K. Bartizal, J. A. Marrinan, W. Li, J. Milligan, K. Nollstadt, and C. M. Douglas. 1996. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun. 64:3244-3251.
14. Lee, M. K., L. E. Williams, D. W. Warnock, and B. A. Arthington-Skaggs. 2004. Drug resistance genes and trailing growth in Candida albicans isolates. J. Antimicrob. Chemother. 53:217-224.
15. Maebashi, K., M. Niimi, M. Kudoh, F. J. Fischer, K. Makimura, K. Niimi, R. J. Piper, K. Uchida, M. Arisawa, R. D. Cannon, and H. Yamaguchi. 2001. Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. J. Antimicrob. Chemother. 47:527-536.
16. Magaldi, S., S. Mata-Essayag, C. Hartung de Capriles, C. Perez, M. T. Colella, C. Olaizola, and Y. Ontiveros. 2004. Well diffusion for antifungal susceptibility testing. Int. J. Infect. Dis. 8:39-45.
17. Marr, K. A., C. N. Lyons, K. Ha, T. R. Rustad, and T. C. White. 2001. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother. 45:52-59.
18. Monk, B. C., R. D. Cannon, K. Nakamura, M. Niimi, K. Niimi, D. R. K. Harding, A. R. Holmes, E. Lamping, A. Goffeau, and A. Decottignies. August 2002. Membrane protein expression system and its application. International patent PCT/NZ02/00163.
19. Monk, B. C., K. Niimi, S. Lin, A. Knight, T. B. Kardos, R. D. Cannon, R. Parshot, A. King, D. Lun, and D. R. Harding. 2005. Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance. Antimicrob. Agents Chemother. 49:57-70.
20. Moudgal, V., T. Little, D. Boikov, and J. A. Vazquez. 2005. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49: 767-769.
21. Nakamura, K., M. Niimi, K. Niimi, A. R. Holmes, J. E. Yates, A. Decottignies, B. C. Monk, A. Goffeau, and R. D. Cannon. 2001. Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob. Agents Chemother. 45:3366-3374.
22. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts, 2nd ed. Approved standard. NCCLS document M27-A2. NCCLS, Wayne, Pa.
23. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. NCCLS, Wayne, Pa.
24. Niimi, K., D. R. Harding, R. Parshot, A. King, D. J. Lun, A. Decottignies, M. Niimi, S. Lin, R. D. Cannon, A. Goffeau, and B. C. Monk. 2004. Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob. Agents Chemother. 48:1256-1271.
25. Niimi, M. 2004. An efficient system for functional hyperexpression of multidrug efflux pumps in Saccharomyces cerevisiae. Nippon Ishinkin Gakkai Zasshi 45: 63-69. (In Japanese.)
26. Niimi, M., Y. Nagai, K. Niimi, S. Wada, R. D. Cannon, Y. Uehara, and B. C. Monk. 2002. Identification of two proteins induced by exposure of the pathogenic fungus Candida glabrata to fluconazole. J. Chromatogr. B 782:245-252.
27. Niimi, M., S. Wada, K. Tanabe, A. Kaneko, Y. Takano, T. Umeyama, N. Hanaoka, Y. Uehara, E. Lamping, K. Niimi, S. Tsao, A. R. Holmes, B. C. Monk, and R. D. Cannon. 2005. Functional analysis of fungal drug efflux transporters by heterologous expression in Saccharomyces cerevisiae. Jpn. J. Infect. Dis. 58:1-7.
28. Paderu, P., S. Park, and D. S. Perlin. 2004. Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob. Agents Chemother. 48:3845-3849.
29. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
30. Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 2003. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. 47:1068-1071.
31. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol. 42:3117-3119.
32. Schuetzer-Muehlbauer, M., B. Willinger, G. Krapf, S. Enzinger, E. Presterl, and K. Kuchler. 2003. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol. Microbiol. 48: 225-235.
33. Smriti, S. Krishnamurthy, B. L. Dixit, C. M. Gupta, S. Milewski, and R. Prasad. 2002. ABC transporters Cdr1p, Cdr2p and Cdr3p of a human pathogen Candida albicans are general phospholipid translocators. Yeast 19:303-318.
34. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
35. Tawara, S., F. Ikeda, K. Maki, Y. Morishita, K. Otomo, N. Teratani, T. Goto, M. Tomishima, H. Ohki, A. Yamada, K. Kawabata, H. Takasugi, K. Sakane, H. Tanaka, F. Matsumoto, and S. Kuwahara. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44:57-62.
36. Tomishima, M., H. Ohki, A. Yamada, H. Takasugi, K. Maki, S. Tawara, and H. Tanaka. 1999. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J. Antibiot. (Tokyo) 52:674-676.
37. Uchida, K., Y. Nishiyama, N. Yokota, and H. Yamaguchi. 2000. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J. Antibiot. (Tokyo) 53:1175-1181.
38. Wada, S., M. Niimi, K. Niimi, A. R. Holmes, B. C. Monk, R. D. Cannon, and Y. Uehara. 2002. Candida glabrata ATP-binding cassette transporters Cdr1p and Pdh1p expressed in a Saccharomyces cerevisiae strain deficient in membrane transporters show phosphorylation-dependent pumping properties. J. Biol. Chem. 277:46809-46821.
39. Wada, S., K. Tanabe, A. Yamazaki, M. Niimi, Y. Uehara, K. Niimi, E. Lamping, R. D. Cannon, and B. C. Monk. 2005. Phosphorylation of Candida glabrata ATP-binding cassette transporter Cdr1p regulates drug efflux activity and ATPase stability. J. Biol. Chem. 280:94-103.